Jason Haas - Net Worth and Insider Trading
Jason Haas Net Worth
The estimated net worth of Jason Haas is at least $315,117 dollars as of 2024-11-05. Jason Haas is the CFO of Syros Pharmaceuticals Inc and owns about 124,552 shares of Syros Pharmaceuticals Inc (SYRS) stock worth over $315,117. Details can be seen in Jason Haas's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jason Haas has not made any transactions after 2024-09-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Jason Haas
Jason Haas Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jason Haas owns 2 companies in total, including Syros Pharmaceuticals Inc (SYRS) , and Ligand Pharmaceuticals Inc (LGND) .
Click here to see the complete history of Jason Haas’s form 4 insider trades.
Insider Ownership Summary of Jason Haas
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SYRS | Syros Pharmaceuticals Inc | 2024-09-12 | Chief Financial Officer |
| LGND | Ligand Pharmaceuticals Inc | 2022-06-29 | director |
Jason Haas Latest Holdings Summary
Jason Haas currently owns a total of 1 stock. Jason Haas owns 124,552 shares of Syros Pharmaceuticals Inc (SYRS) as of September 12, 2024, with a value of $315,117.
Latest Holdings of Jason Haas
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SYRS | Syros Pharmaceuticals Inc | 2024-09-12 | 124,552 | 2.53 | 315,117 |
Holding Weightings of Jason Haas
Jason Haas Form 4 Trading Tracker
According to the SEC Form 4 filings, Jason Haas has made a total of 1 transactions in Syros Pharmaceuticals Inc (SYRS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Syros Pharmaceuticals Inc is the acquisition of 100,000 shares on September 12, 2024, which cost Jason Haas around $161,000.
Insider Trading History of Jason Haas
- 1
Jason Haas Trading Performance
GuruFocus tracks the stock performance after each of Jason Haas's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jason Haas is %. GuruFocus also compares Jason Haas's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jason Haas within 3 months outperforms times out of transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jason Haas's insider trading performs compared to the benchmark.
Performance of Jason Haas
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 22.93 |  | | | | |
| Relative Return to S&P 500(%) | 19.01 | | | | | |
Jason Haas Ownership Network
Ownership Network List of Jason Haas
Ownership Network Relation of Jason Haas
Jason Haas Owned Company Details
What does Syros Pharmaceuticals Inc do?
Who are the key executives at Syros Pharmaceuticals Inc?
Jason Haas is the Chief Financial Officer of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include Chief Commercial Officer Chee Conley , Chief Medical Officer David Roth , and Chief Scientific Officer Eric R Olson .
Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary
Over the past 18 months, Jason Haas made 1 insider transaction in Syros Pharmaceuticals Inc (SYRS) with a net purchase of 100,000. Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 30,523 shares made by David Roth , a net purchase of 904,977 shares made by Srinivas Akkaraju , and a net purchase of 100,000 shares made by Chee Conley .
In summary, during the past 3 months, insiders sold 0 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 200,000 shares, with a net purchase of 200,000 shares. During the past 18 months, 31,212 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 1,104,977 shares were bought by its insiders, resulting in a net purchase of 1,073,765 shares.
Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Syros Pharmaceuticals Inc Insider Transactions
Jason Haas Mailing Address
Above is the net worth, insider trading, and ownership report for Jason Haas. You might contact Jason Haas via mailing address: C/o Syros Pharmaceuticals, Inc., 35 Cambridgepark Drive, Cambridge Ma 02140.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
